Author

K. Baker

Observed names: Katherine Baker, Katherine Plumblee Baker

Institution: Tennessee Oncology

Observed institutions: Tennessee Oncology, Syros Pharmaceuticals (United States), Vanderbilt University Medical Center

ORCID: 0009-0001-9566-017X

Observed ORCID: 0009-0001-9566-017X

OpenAlex ID: A5043457415

EP.17E.02 Assessing the True Cost of Lung Cancer Screening - Chargemaster, Payer, And Cash Price Discrepancies for CT Chest Imaging

2024 · M.N. Alford-Holloway, A. Triana, et al. · Journal of Thoracic Oncology · 1

Assessing the true cost of infusion care: Comparing hospital chargemaster, cash, and negotiated prices for infusion CPT codes across top-ranked US hospitals.

2026 · Mason Nicholas Alford-Holloway, Austin Triana, et al. · Journal of Clinical Oncology

Copay accumulators: Shifting costs of oncology drugs from plans to patients

2024 · Katherine Plumblee Baker, Samyukta Mullangi · Cancer

P492: Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for Rara-positive Aml Who Are Ineligible for Standard Induction Therapy (select Aml-1)

2022 · E. Stein, S. de Botton, et al. · HemaSphere

Pb1921: a Randomized, Double-blind, Phase 3 Study of Tamibarotene/azacitidine Versus Placebo/azacitidine in Newly Diagnosed Adult Patients Selected for Rara-positive Hr-mds (select-mds-1)

2022 · A. DeZern, G. Marconi, et al. · HemaSphere

Works count: 5

Citation count: 1

H-index: 1

I10-index: